Hussein Badr

Jan 2024 - Present: Oncology and Hematology Line.

• Managing the oral and injectable oncology and hematology portfolio of 33 products.
• Organize training sessions for the sales team to enhance their understanding of the product portfolio.
• Identify market segments, competitive positioning, development trends, and growth opportunities.
• Conducted extensive market analysis, planned for new product introductions, and developed strategic marketing plans.
• Work collaboratively with R&D, manufacturing, sales, and other stakeholders to ensure seamless product launches.
• Analyze product performance, manage risks, and forecast sales.

Achievements:

• Adopting retail expansion strategy which lead to doubling contribution of retail segment vs tender segment in hikma's sales

Jul 2023 - Dec 2023:

Injectables Line (Anti-infectives and Injectafer)

• Managing a portfolio of anti-infectives, including Tigecycline, Ceftazidime, and Piperacillin/Tazobactam.
• Responsible for the marketing plan for Injectafer, the first ferric carboxymaltose brand to be marketed in Egypt.
• Participated in mapping the competitive landscape for a previously unexplored specialty, "Gynecology," to Hikma, and organizing pre-launch activities for Injectafer.

Specialized Line

• Managing immunosuppressant Prograf and Advagraf.
• Developed robust relationships with key transplant opinion leaders to safeguard Prograf's positioning against the generic Adport.
• Maintained MS% of 75% despite extensive activities and investment from the competitor.

Appraisal:

• 2023: Meet expectations.
• 2024: Exceed Expectations.

Feb 2020 - Dec 2020:

• Injectable chemotherapy line.

Jan 2021 - Jun 2023:

• Oral Hematology Line.

Key Responsibilities:

• Follow all relevant sales procedures to ensure that work is carried out in a controlled and consistent manner.
• Regular HCPs visit private clinics and hospitals daily to promote products, share product information, and communicate company messages to achieve monthly sales targets.
• Covered areas: Cairo, Giza, Delta (Zagazig), Canal (Ismailia and Port Said), and Upper Egypt (Assiut, Sohag, Qena, Luxor, and Aswan).

Appraisal:

• 2020 and 2021: Meet Expectations.
• 2022: Exceed Expectations

Awards:

• 2021: Special Award.
• 2022: Best Performer.

• Part-time medical representative responsible for the promotion of nutraceuticals in Sharqeya to achieve sales targets.

Raw Materials Department:

• Responsible for analytical and instrumental analysis of raw materials (active and inactive pharmaceutical ingredients).
• Complying with analysis specifications and adhering to GLP during the analysis of raw materials.
• Performing Out of Specifications (OOS) for nonconforming raw materials.

Sterile Cephalosporins area.

Ensure compliance with all manufacturing steps to the company's SOPs, GMP, and WHO criteria for sterile areas.

Reviewing batch records and release when complying with all internal SOPs.